Metraipolis › archive › dc_ecdcc0843c03
Redefining uUTI therapy: Orlynvah as a promising oral alternative (sulopenem etzadroxil and probenecid) — Europe PMC PMID:41180696
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41180696
- DOI
- 10.1097/ms9.0000000000003933
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T19:33:56.124Z
- SHA-256 of the archived text
c94d306da1b2c63a6d3e62cfbecf5b117d3a65f87255d16a1f6e0e4fd30d948c- Stable URL of this page
https://metraipolis.com/documento/dc_ecdcc0843c03
How to cite
Redefining uUTI therapy: Orlynvah as a promising oral alternative (sulopenem etzadroxil and probenecid) — Europe PMC PMID:41180696 — Europe PMC (en), https://europepmc.org/article/MED/41180696 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ecdcc0843c03 (Metraipolis archive dc_ecdcc0843c03, sha256 c94d306da1b2c63a6d3e62cfbecf5b117d3a65f87255d16a1f6e0e4fd30d948c)
BibTeX
@misc{dcecdcc0843c03,
title = {Redefining uUTI therapy: Orlynvah as a promising oral alternative (sulopenem etzadroxil and probenecid) — Europe PMC PMID:41180696},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41180696},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ecdcc0843c03; sha256 c94d306da1b2c63a6d3e62cfbecf5b117d3a65f87255d16a1f6e0e4fd30d948c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41180696. Agents can read the archived copy with the MCP tool read_document.